ASCP Corner: Clinical Psychopharmacology of Pediatric Mood Stabilizer and Antipsychotic Treatment, Part 2: Methodological Considerations
J Clin Psychiatry 2007;68:1441-1442
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
In last month’s ASCP Corner, I discussed some of the challenges and recent developments regarding the available evidence base for the use of antipsychotics and mood stabilizers in children and adolescents. 1 In this month’s column, I will focus on some of the pertinent clinical psychopharmacology trials design issues that are relevant to the collection of data in children and adolescents who are in need of antipsychotic or mood stabilizer treatment.
While it is clear that studying psychotropic medication effects in children and adolescents is crucial, it is also a difficult task.